Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Newly Added Patents
About This List
- This screen lists the current month's NEW ADDITIONS or NEW CHANGES to the patents for drugs listed in the Orange Book.
- This list will be purged after the Cumulative Supplement to the Orange Book is published on the first day of the next month. All the information listed on this screen is also available by using the other Orange Book search methods, such as searching by Proprietary Name.
- Patents will remain available in the Orange Book even when they are no longer listed as NEW additions or NEW changes.
Additional Information about Patents
- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.
| Appl No | Active Ingredient | Proprietary Name | Dosage Form | Route | Strength | Patent No | Patent Expire Date | Drug Substance | Drug Product | Patent Use Code | Delist Requested | Mkt. Status | Submission Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appl No | Active Ingredient | Proprietary Name | Dosage Form | Route | Strength | Patent No | Patent Expire Date | Drug Substance | Drug Product | Patent Use Code | Delist Requested | Mkt. Status | Submission Date |
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 10017491 | 12/28/2032 | DP | RX | 11/14/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 10034879 | 12/28/2032 | DS | DP | RX | 11/14/2022 | ||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 10189833 | 05/05/2036 | U-2606 | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 10220155 | 07/17/2026 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 10335462 | 06/21/2033 | DP | U-2580 | RX | 11/14/2022 | ||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 10357616 | 01/20/2026 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 10376652 | 01/20/2026 | DP | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 10435404 | 07/24/2038 | DP | RX | 11/14/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 10493035 | 10/12/2037 | DP | RX | 11/14/2022 | |||
| N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 10570139 | 04/22/2034 | U-1745 | RX | 06/04/2021 | |||
| N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 10570139 | 04/22/2034 | U-3063 | RX | 06/04/2021 | |||
| N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 10570139 | 04/22/2034 | U-2145 | RX | 06/04/2021 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 10722502 | 02/06/2035 | DP | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 10730876 | 05/05/2036 | DS | RX | 11/14/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 10806733 | 12/28/2032 | DS | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 10941142 | 07/24/2038 | DP | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 10961240 | 07/24/2038 | U-2606 | RX | 11/14/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 1.4553GM/3ML (485.1MG/ML) | 10973934 | 08/06/2039 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 3.63825GM/7.5ML (485.1MG/ML) | 10973934 | 08/06/2039 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 4.851GM/10ML (485.1MG/ML) | 10973934 | 08/06/2039 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 7.2765GM/15ML (485.1MG/ML) | 10973934 | 08/06/2039 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 14.553GM/30ML (485.1MG/ML) | 10973934 | 08/06/2039 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 24.255GM/50ML (485.1MG/ML) | 10973934 | 08/06/2039 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 48.51GM/100ML (485.1MG/ML) | 10973934 | 08/06/2039 | DS | RX | 11/28/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 11020382 | 12/02/2036 | U-3134 | RX | 11/14/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 11020382 | 12/02/2036 | U-3133 | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 11097063 | 07/17/2026 | DP | RX | 11/14/2022 | |||
| N208692 | CABOZANTINIB S-MALATE | CABOMETYX | TABLET | ORAL | EQ 60MG BASE | 11141413 | 04/17/2037 | U-3239 | Y | RX | 11/05/2021 | ||
| N208692 | CABOZANTINIB S-MALATE | CABOMETYX | TABLET | ORAL | EQ 40MG BASE | 11141413 | 04/17/2037 | U-3239 | Y | RX | 11/05/2021 | ||
| N208692 | CABOZANTINIB S-MALATE | CABOMETYX | TABLET | ORAL | EQ 20MG BASE | 11141413 | 04/17/2037 | U-3239 | Y | RX | 11/05/2021 | ||
| N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11142528 | 04/22/2034 | DP | U-1745 | RX | 11/12/2021 | ||
| N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11142528 | 04/22/2034 | DP | U-3063 | RX | 11/12/2021 | ||
| N213217 | ZANUBRUTINIB | BRUKINSA | CAPSULE | ORAL | 80MG | 11142528 | 04/22/2034 | DP | U-2145 | RX | 11/12/2021 | ||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 11311679 | 01/20/2026 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 11446443 | 10/20/2025 | DP | RX | 11/14/2022 | |||
| N022496 | BUPIVACAINE | EXPAREL | INJECTABLE, LIPOSOMAL | INJECTION | 133MG/10ML (13.3MG/ML) | 11452691 | 01/22/2041 | DP | U-3439 | RX | 10/04/2022 | ||
| N213388 | ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM | ORIAHNN (COPACKAGED) | CAPSULE | ORAL | EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE | 11459305 | 11/07/2028 | DP | U-2842 | RX | 11/02/2022 | ||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 10MG | 11464423 | 09/15/2030 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 5MG | 11464423 | 09/15/2030 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 30MG | 11464423 | 09/15/2030 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 15MG | 11464423 | 09/15/2030 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 2MG | 11464423 | 09/15/2030 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 20MG | 11464423 | 09/15/2030 | DP | RX | 11/09/2022 | |||
| N208088 | TESTOSTERONE UNDECANOATE | TLANDO | CAPSULE | ORAL | 112.5MG | 11464735 | 04/28/2041 | DP | U-1500 | RX | 11/10/2022 | ||
| N208798 | FLUTICASONE PROPIONATE | ARMONAIR DIGIHALER | POWDER | INHALATION | 0.03MG/INH | 11464923 | 06/19/2040 | DP | DISCN | 11/10/2022 | |||
| N205636 | ALBUTEROL SULFATE | PROAIR DIGIHALER | POWDER, METERED | INHALATION | EQ 0.09MG BASE/INH | 11464923 | 06/19/2040 | DP | RX | 11/10/2022 | |||
| N208799 | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | AIRDUO DIGIHALER | POWDER | INHALATION | 0.113MG/INH;EQ 0.014MG BASE/INH | 11464923 | 06/19/2040 | DP | RX | 11/10/2022 | |||
| N208799 | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | AIRDUO DIGIHALER | POWDER | INHALATION | 0.232MG/INH;EQ 0.014MG BASE/INH | 11464923 | 06/19/2040 | DP | RX | 11/10/2022 | |||
| N208799 | FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | AIRDUO DIGIHALER | POWDER | INHALATION | 0.055MG/INH;EQ 0.014MG BASE/INH | 11464923 | 06/19/2040 | DP | RX | 11/10/2022 | |||
| N208798 | FLUTICASONE PROPIONATE | ARMONAIR DIGIHALER | POWDER | INHALATION | 0.232MG/INH | 11464923 | 06/19/2040 | DP | RX | 11/10/2022 | |||
| N208798 | FLUTICASONE PROPIONATE | ARMONAIR DIGIHALER | POWDER | INHALATION | 0.113MG/INH | 11464923 | 06/19/2040 | DP | RX | 11/10/2022 | |||
| N208798 | FLUTICASONE PROPIONATE | ARMONAIR DIGIHALER | POWDER | INHALATION | 0.055MG/INH | 11464923 | 06/19/2040 | DP | RX | 11/10/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 10MG | 11476952 | 04/28/2026 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 5MG | 11476952 | 04/28/2026 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 30MG | 11476952 | 04/28/2026 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 15MG | 11476952 | 04/28/2026 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 2MG | 11476952 | 04/28/2026 | DP | RX | 11/09/2022 | |||
| N207202 | ARIPIPRAZOLE | ABILIFY MYCITE KIT | TABLET | ORAL | 20MG | 11476952 | 04/28/2026 | DP | RX | 11/09/2022 | |||
| N215390 | DEXMEDETOMIDINE HYDROCHLORIDE | IGALMI | FILM | BUCCAL, SUBLINGUAL | EQ 0.12MG BASE | 11478422 | 06/26/2039 | DP | RX | 11/22/2022 | |||
| N215390 | DEXMEDETOMIDINE HYDROCHLORIDE | IGALMI | FILM | BUCCAL, SUBLINGUAL | EQ 0.18MG BASE | 11478422 | 06/26/2039 | DP | RX | 11/22/2022 | |||
| N213407 | EPHEDRINE SULFATE | EMERPHED | SOLUTION | INTRAVENOUS | 50MG/10ML (5MG/ML) | 11478436 | 05/16/2040 | U-3183 | RX | 11/18/2022 | |||
| N215446 | EDARAVONE | RADICAVA ORS | SUSPENSION | ORAL | 105MG/5ML | 11478450 | 11/01/2039 | U-3468 | RX | 11/15/2022 | |||
| N215430 | BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE | AUVELITY | TABLET, EXTENDED RELEASE | ORAL | 105MG;45MG | 11478468 | 11/05/2034 | U-3419 | RX | 11/10/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 750MG IRON/15ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3472 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 750MG IRON/15ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3473 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 750MG IRON/15ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3474 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 500MG IRON/10ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3472 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 500MG IRON/10ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3473 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 500MG IRON/10ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3474 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 1GM IRON/20ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3472 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 1GM IRON/20ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3473 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 1GM IRON/20ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3474 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 100MG IRON/2ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3472 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 100MG IRON/2ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3473 | RX | 11/21/2022 | |||
| N203565 | FERRIC CARBOXYMALTOSE | INJECTAFER | SOLUTION | INTRAVENOUS | 100MG IRON/2ML (50MG IRON/ML) | 11478502 | 01/08/2027 | U-3474 | RX | 11/21/2022 | |||
| N206940 | ELUXADOLINE | VIBERZI | TABLET | ORAL | 100MG | 11484527 | 03/14/2033 | U-3475 | RX | 11/22/2022 | |||
| N209394 | GLECAPREVIR; PIBRENTASVIR | MAVYRET | TABLET | ORAL | 100MG;40MG | 11484534 | 03/14/2034 | U-3237 | RX | 11/30/2022 | |||
| N209394 | GLECAPREVIR; PIBRENTASVIR | MAVYRET | TABLET | ORAL | 100MG;40MG | 11484534*PED | 09/14/2034 | RX | |||||
| N201688 | TOBRAMYCIN | TOBI PODHALER | POWDER | INHALATION | 28MG | 11484671 | 11/07/2024 | DP | U-909 | RX | 11/18/2022 | ||
| N209478 | SPIRONOLACTONE | CAROSPIR | SUSPENSION | ORAL | 25MG/5ML | 11491166 | 10/28/2036 | DP | RX | 11/18/2022 | |||
| N208564 | ESTRADIOL | IMVEXXY | INSERT | VAGINAL | 0.01MG | 11497709 | 11/21/2032 | U-2317 | RX | 11/21/2022 | |||
| N208564 | ESTRADIOL | IMVEXXY | INSERT | VAGINAL | 0.01MG | 11497709 | 11/21/2032 | U-2316 | RX | 11/21/2022 | |||
| N208564 | ESTRADIOL | IMVEXXY | INSERT | VAGINAL | 0.004MG | 11497709 | 11/21/2032 | U-2317 | RX | 11/21/2022 | |||
| N208564 | ESTRADIOL | IMVEXXY | INSERT | VAGINAL | 0.004MG | 11497709 | 11/21/2032 | U-2316 | RX | 11/21/2022 | |||
| N215390 | DEXMEDETOMIDINE HYDROCHLORIDE | IGALMI | FILM | BUCCAL, SUBLINGUAL | EQ 0.12MG BASE | 11497711 | 06/26/2039 | DP | RX | 11/15/2022 | |||
| N215390 | DEXMEDETOMIDINE HYDROCHLORIDE | IGALMI | FILM | BUCCAL, SUBLINGUAL | EQ 0.18MG BASE | 11497711 | 06/26/2039 | DP | RX | 11/15/2022 | |||
| N215430 | BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE | AUVELITY | TABLET, EXTENDED RELEASE | ORAL | 105MG;45MG | 11497721 | 11/05/2034 | U-3419 | RX | 12/02/2022 | |||
| N213312 | SIROLIMUS | FYARRO | POWDER | INTRAVENOUS | 100MG/VIAL | 11497737 | 10/28/2040 | DP | RX | 11/23/2022 | |||
| N214662 | MARALIXIBAT CHLORIDE | LIVMARLI | SOLUTION | ORAL | EQ 9.5MG BASE/ML | 11497745 | 02/12/2040 | U-3290 | RX | 11/30/2022 | |||
| N216264 | INDIGOTINDISULFONATE SODIUM | BLUDIGO | SOLUTION | INTRAVENOUS | 40MG/5ML (8MG/ML) | 11499050 | 12/23/2037 | DS | RX | 11/30/2022 | |||
| N212904 | TIVOZANIB HYDROCHLORIDE | FOTIVDA | CAPSULE | ORAL | EQ 0.89MG BASE | 11504365 | 11/05/2039 | U-3476 | RX | 12/01/2022 | |||
| N212904 | TIVOZANIB HYDROCHLORIDE | FOTIVDA | CAPSULE | ORAL | EQ 1.34MG BASE | 11504365 | 11/05/2039 | U-3476 | RX | 12/01/2022 | |||
| N216018 | RANOLAZINE | ASPRUZYO SPRINKLE | GRANULES, EXTENDED RELEASE | ORAL | 500MG | 11510878 | 01/24/2038 | DP | RX | 12/01/2022 | |||
| N216018 | RANOLAZINE | ASPRUZYO SPRINKLE | GRANULES, EXTENDED RELEASE | ORAL | 1GM | 11510878 | 01/24/2038 | DP | RX | 12/01/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 7762994 | 05/23/2024 | DP | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 7893075 | 05/04/2033 | DS | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 8114833 | 08/13/2025 | DP | RX | 11/14/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 1.4553GM/3ML (485.1MG/ML) | 8114863 | 09/19/2028 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 3.63825GM/7.5ML (485.1MG/ML) | 8114863 | 09/19/2028 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 4.851GM/10ML (485.1MG/ML) | 8114863 | 09/19/2028 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 7.2765GM/15ML (485.1MG/ML) | 8114863 | 09/19/2028 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 14.553GM/30ML (485.1MG/ML) | 8114863 | 09/19/2028 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 24.255GM/50ML (485.1MG/ML) | 8114863 | 09/19/2028 | DS | RX | 11/28/2022 | |||
| N216986 | GADOPICLENOL | ELUCIREM | SOLUTION | INTRAVENOUS | 48.51GM/100ML (485.1MG/ML) | 8114863 | 09/19/2028 | DS | RX | 11/28/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 8129343 | 12/05/2031 | DS | DP | U-3469 | RX | 11/14/2022 | |
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 8404700 | 11/21/2027 | DS | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 8461169 | 04/19/2028 | U-2606 | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 8536122 | 03/20/2026 | DS | DP | U-3469 | RX | 11/14/2022 | |
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 8579869 | 06/30/2023 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 8684969 | 10/20/2025 | DP | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 8722702 | 11/21/2027 | DS | RX | 11/14/2022 | |||
| N208464 | TENOFOVIR ALAFENAMIDE FUMARATE | VEMLIDY | TABLET | ORAL | EQ 25MG BASE | 8754065 | 08/15/2032 | DS | DP | U-999 | RX | 11/28/2016 | |
| N208464 | TENOFOVIR ALAFENAMIDE FUMARATE | VEMLIDY | TABLET | ORAL | EQ 25MG BASE | 8754065 | 08/15/2032 | DS | DP | U-1275 | RX | 11/28/2016 | |
| N208464 | TENOFOVIR ALAFENAMIDE FUMARATE | VEMLIDY | TABLET | ORAL | EQ 25MG BASE | 8754065*PED | 02/15/2033 | RX | |||||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 8920383 | 07/17/2026 | DP | RX | 11/14/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 500MG | 9018210 | 11/25/2033 | DS | DP | RX | 12/19/2019 | ||
| N216157 | VOXELOTOR | OXBRYTA | TABLET, FOR SUSPENSION | ORAL | 300MG | 9018210 | 11/25/2033 | DS | DP | RX | 01/14/2022 | ||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 9018210 | 11/25/2033 | DS | DP | RX | 11/14/2022 | ||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 9108002 | 01/20/2026 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 9132239 | 02/01/2032 | DP | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 9169250 | 11/21/2027 | DS | RX | 11/14/2022 | |||
| N209445 | CEFIDEROCOL SULFATE TOSYLATE | FETROJA | POWDER | INTRAVENOUS | EQ 1GM BASE/VIAL | 9238657 | 11/14/2033 | DS | DP | U-282 | RX | 12/11/2019 | |
| N209445 | CEFIDEROCOL SULFATE TOSYLATE | FETROJA | POWDER | INTRAVENOUS | EQ 1GM BASE/VIAL | 9238657 | 11/14/2033 | DS | DP | U-3470 | RX | 12/11/2019 | |
| N209445 | CEFIDEROCOL SULFATE TOSYLATE | FETROJA | POWDER | INTRAVENOUS | EQ 1GM BASE/VIAL | 9238657 | 11/14/2033 | DS | DP | U-3471 | RX | 12/11/2019 | |
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 9248199 | 01/29/2034 | U-2676 | RX | 11/14/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 9248199 | 01/29/2034 | U-2715 | RX | 11/14/2022 | |||
| N205029 | EPINEPHRINE | EPINEPHRINE | SOLUTION | INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS | 1MG/ML (1MG/ML) | 9283197 | 08/15/2034 | DP | U-1829 | Y | RX | 04/07/2016 | |
| N205029 | EPINEPHRINE | EPINEPHRINE | SOLUTION | INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS | 1MG/ML (1MG/ML) | 9283197 | 08/15/2034 | DP | U-1828 | Y | RX | 04/07/2016 | |
| N205029 | EPINEPHRINE | EPINEPHRINE | SOLUTION | INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS | 1MG/ML (1MG/ML) | 9283197 | 08/15/2034 | DP | U-1830 | Y | RX | 04/07/2016 | |
| N208464 | TENOFOVIR ALAFENAMIDE FUMARATE | VEMLIDY | TABLET | ORAL | EQ 25MG BASE | 9296769 | 08/15/2032 | DS | DP | U-999 | RX | 11/28/2016 | |
| N208464 | TENOFOVIR ALAFENAMIDE FUMARATE | VEMLIDY | TABLET | ORAL | EQ 25MG BASE | 9296769 | 08/15/2032 | DS | DP | U-1275 | RX | 11/28/2016 | |
| N208464 | TENOFOVIR ALAFENAMIDE FUMARATE | VEMLIDY | TABLET | ORAL | EQ 25MG BASE | 9296769*PED | 02/15/2033 | RX | |||||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 9358235 | 06/08/2033 | U-2606 | RX | 11/14/2022 | |||
| N213137 | VOXELOTOR | OXBRYTA | TABLET | ORAL | 300MG | 9447071 | 02/06/2035 | DS | DP | RX | 11/14/2022 | ||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 9457154 | 09/29/2027 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 9616180 | 01/20/2026 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 9687611 | 02/27/2027 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 9775953 | 07/17/2026 | DP | RX | 11/14/2022 | |||
| N211810 | PEXIDARTINIB HYDROCHLORIDE | TURALIO | CAPSULE | ORAL | EQ 125MG BASE | 9802932 | 05/05/2036 | DS | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | 9861757 | 01/20/2026 | DP | RX | 11/14/2022 | |||
| N209637 | SEMAGLUTIDE | OZEMPIC | SOLUTION | SUBCUTANEOUS | 2MG/3ML (0.68MG/ML) | RE46363 | 08/03/2026 | DP | RX | 11/14/2022 |
View a list of all patent use codes
View a list of all exclusivity codes
Last Updated December 05, 2022.